Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2016 - 2025)

Vanda Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 141213000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 2774.86% year-over-year to 141213000.0; the TTM value through Dec 2025 reached 220474000.0, down 1066.53%, while the annual FY2025 figure was 220474000.0, 1066.53% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 141213000.0 at Vanda Pharmaceuticals, down from 22586000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 9675000.0 in Q2 2021 and bottomed at 141213000.0 in Q4 2025.
  • The 5-year median for Income from Continuing Operations is 1131500.0 (2023), against an average of 9867350.0.
  • The largest annual shift saw Income from Continuing Operations surged 1675.31% in 2021 before it tumbled 3986.13% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 7127000.0 in 2021, then decreased by 3.35% to 6888000.0 in 2022, then plummeted by 134.84% to 2400000.0 in 2023, then crashed by 104.67% to 4912000.0 in 2024, then plummeted by 2774.86% to 141213000.0 in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Income from Continuing Operations are 141213000.0 (Q4 2025), 22586000.0 (Q3 2025), and 27207000.0 (Q2 2025).